Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27112377 | 0.95 | L3MBTL1 (0.31) | L3MBTL1 | |
| SCHEMBL24760754 | 0.95 | L3MBTL1 (0.31) | L3MBTL1 | |
| SCHEMBL24760968 | 0.81 | — | — | |
| SCHEMBL25540260 | 0.80 | L3MBTL1 (0.36) | L3MBTL1HTTCHRNB4CHRNA3 | |
| SCHEMBL23372707 | 0.76 | L3MBTL1 (0.38) | L3MBTL1HTT | |
| SCHEMBL12299850 | 0.75 | L3MBTL1 (0.40) | L3MBTL1HTT | |
| SCHEMBL12658780 | 0.75 | L3MBTL1 (0.40) | L3MBTL1HTT | |
| SCHEMBL12658782 | 0.75 | L3MBTL1 (0.40) | L3MBTL1HTT | |
| SCHEMBL23546161 | 0.72 | KDM4E (0.35) | — | |
| SCHEMBL3535268 | 0.72 | L3MBTL1 (0.38) | L3MBTL1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402904-A1 | 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione Derivatives and Uses thereof | NOVARTIS AG (CH) | 2022-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402904-A1 | 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione Derivatives and Uses thereof | HBZ, ZFX, HBG1 | L3MBTL1 391/4885HTT 1280/4885CHRNB4 2867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.